Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Q-Line BiotechNSE:QLINE -1.12%14 Return-on-Tangible-Asset is 7.34% as of Mar. 2025, which is 38% below its 10-year median of 11.76. GuruFocus rates NSE:QLINE with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 855 Medical Devices & Instruments companies, Q-Line Biotech ranks better than 74.15% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Q-Line Biotech's annualizedNet Income for the quarter that ended in Mar. 2025 was ₹281 Mil. Q-Line Biotech's average total tangible assets for the quarter that ended in Mar. 2025 was ₹3,830 Mil. Therefore, Q-Line Biotech's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 was 7.34%.
The historical rank and industry rank for Q-Line Biotech's Return-on-Tangible-Asset or its related term are showing as below:
NSE:QLINE'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 7.34 Med: 11.76 Max: 12.76
Current: 7.34
During the past 3 years, Q-Line Biotech's highest Return-on-Tangible-Asset was 12.76%. The lowest was 7.34%. And the median was 11.76%.
NSE:QLINE's Return-on-Tangible-Asset is ranked better than 74.15% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 0.74
vs NSE:QLINE: 7.34
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Q-Line Biotech Return-on-Tangible-Asset Related Terms
Q-Line Biotech Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Q-Line Biotech's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-Line Biotech Return-on-Tangible-Asset Chart
Q-Line Biotech Annual Data
Trend
Mar23
Mar24
Mar25
Return-on-Tangible-Asset
12.76
11.76
7.34
Q-Line Biotech Semi-Annual Data
Mar23
Mar24
Mar25
Return-on-Tangible-Asset
12.76
11.76
7.34
NSE:QLINE vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Q-Line Biotech's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-Line Biotech Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-Line Biotech's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Q-Line Biotech's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is one times the annual (Mar. 2025) net income data.
What does a Return-on-Tangible-Asset of 7.34% mean?
Q-Line Biotech (NSE:QLINE) has a Return-on-Tangible-Asset of 7.34% as of Mar. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Q-Line Biotech and its competitors. This is 38% below median its historical median of 11.76. Over the past decade, Q-Line Biotech's Return-on-Tangible-Asset has ranged from 7.34 to 12.76. According to the industry distribution chart, Q-Line Biotech ranks #221 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 25.8%.
Is Q-Line Biotech's Return-on-Tangible-Asset too high?
Q-Line Biotech's current Return-on-Tangible-Asset of 7.34% is 38% below median its 10-year median of 11.76. Over the past 10 years, this metric has ranged from a low of 7.34 to a high of 12.76. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.74. Q-Line Biotech's value of 7.34% is 891.9% above this industry median. Based on the distribution chart, Q-Line Biotech ranks #221 out of 855 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Q-Line Biotech has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Q-Line Biotech's Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-Line Biotech ranks #221 out of 855 companies for Return-on-Tangible-Asset. This puts Q-Line Biotech in the upper half of its industry. The industry median Return-on-Tangible-Asset is 0.74. Q-Line Biotech's value of 7.34% is 891.9% above this benchmark. Historically, Q-Line Biotech's own Return-on-Tangible-Asset has ranged from 7.34 to 12.76 over the past decade. While the company's 10-year median is 11.76 vs. the industry median of 0.74, Q-Line Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.74, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Q-Line Biotech's current Return-on-Tangible-Asset of 7.34% is 891.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Q-Line Biotech and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-Line Biotech's current Return-on-Tangible-Asset is 7.34%, which is 38% below median its own 10-year median of 11.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-Line Biotech stock overvalued right now?
Q-Line Biotech (NSE:QLINE) has a current Return-on-Tangible-Asset of 7.34%. The current Return-on-Tangible-Asset is 7.34%, which is 38% below median its 10-year median of 11.76 and 891.9% above the Medical Devices & Instruments industry median of 0.74. Q-Line Biotech's overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Q-Line Biotech (NSE:QLINE), the current Return-on-Tangible-Asset is 7.34% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
14GF Score
Get the complete analysis for NSE:QLINE
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QLINE has been successfully added to your 
